LEADER 02941oam  2200457   450 
001 9910136407603321
005 20230621135800.0
010   $a9782889193325 (ebook)
035   $a(CKB)3710000000612036
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45512
035   $a(EXLCZ)993710000000612036
100   $a20191103c2014uuuu  uu             |
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug-diagnostics co-development in oncology$b[electronic resource] /$ftopic editor Jan Trøst Jørgensen
210   $cFrontiers Media SA$d2014
210  1$aFrance :$cFrontiers Media SA,$d2014
215   $a1 online resource (111 pages) $ccolour illustrations, charts
225 1 $aFrontiers Research Topics
320   $aIncludes bibliographical references.
330   $aThe idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970?s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest?, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs.
606   $aOncology
610   $aIHC
610   $afish
610   $aprecision medicine
610   $aNGS
610   $aDrug-diagnostic co-development
610   $acompanion diagnostics
610   $aoncology
610   $apersonalized medicine
615  0$aOncology.
676   $a615.1/9
700   $aJan Trost Jorgensen$4auth$01367185
702   $aJørgensen$b Jan Trøst
801  0$bUkMaJRU
912   $a9910136407603321
996   $aDrug-diagnostics co-development in oncology$93389914
997   $aUNINA